Organon & Co. (NYSE:OGN) Shares Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC boosted its stake in Organon & Co. (NYSE:OGN) by 230.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,607 shares of the company’s stock after buying an additional 113,416 shares during the period. Exchange Traded Concepts LLC’s holdings in Organon & Co. were worth $3,111,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its position in Organon & Co. by 200.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares during the last quarter. William B. Walkup & Associates Inc. acquired a new stake in shares of Organon & Co. in the second quarter valued at approximately $31,000. Atlas Capital Advisors LLC raised its holdings in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after buying an additional 2,147 shares during the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Organon & Co. during the first quarter worth approximately $43,000. Finally, Tompkins Financial Corp grew its holdings in Organon & Co. by 450.7% in the 1st quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after buying an additional 1,974 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

OGN has been the topic of several recent analyst reports. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Trading Up 0.6 %

Shares of NYSE:OGN opened at $18.11 on Tuesday. The firm has a market capitalization of $4.66 billion, a P/E ratio of 4.43, a price-to-earnings-growth ratio of 0.79 and a beta of 0.84. The firm has a fifty day moving average of $20.10 and a two-hundred day moving average of $20.17. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last released its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same quarter in the previous year, the business earned $1.31 EPS. The business’s revenue was down .1% on a year-over-year basis. On average, equities analysts expect that Organon & Co. will post 4.15 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.19%. The ex-dividend date was Friday, August 16th. Organon & Co.’s payout ratio is 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.